Abiraterone Acetate

Form: Tablet

Strength: 250 mg, 500 mg

Reference Brands: Zytiga®(EU & US)

Category: Oncology Cancer Care

Abiraterone Acetate Tablets, available in 250 mg and 500 mg strengths, are a key oral oncology product used in treating metastatic prostate cancer. Approved across the U.S. and EU, Abiraterone inhibits androgen biosynthesis by targeting the CYP17 enzyme, effectively suppressing tumor growth in hormone-sensitive prostate cancers. Marketed under the brand name Zytiga® and widely available as generics, this therapy is often used alongside prednisone. Abiraterone Acetate is a vital product for pharma B2B oncology portfolios, offering significant therapeutic benefit and global demand in both hospital and retail oncology markets.